Examkin

Question

Difficulty: HardPreventive Care and Immunizations

A toddler is evaluated at the pediatric clinic for a health maintenance visit at 15 months of age. His mother reports that he has been doing well since a hospitalization 5 months ago. At that time, he presented with 6 days of high fever, bilateral nonexudative conjunctivitis, erythema of the oral mucosa, and a generalized maculopapular rash. He was successfully treated in the hospital and discharged home. The patient currently takes daily low-dose aspirin and has no other medical conditions. He previously received all routine immunizations up to 6 months of age, but has not received any vaccines since then. His temperature is 37.1 C (98.8 F), blood pressure is 90/55 mm Hg, pulse is 110/min, and respirations are 24/min. Physical examination today is unremarkable. Which of the following is the most appropriate immunization plan for this patient today?

  1. Administer DTaP, Haemophilus influenzae type b, pneumococcal conjugate, and hepatitis A vaccines; defer measles-mumps-rubella and varicella vaccines.Answer
  2. B
    Administer DTaP, Haemophilus influenzae type b, pneumococcal conjugate, hepatitis A, measles-mumps-rubella, and varicella vaccines.
  3. C
    Defer all immunizations until 11 months have passed since his hospital discharge.
  4. D
    Defer all immunizations until the patient has completely discontinued daily aspirin therapy.
  5. E
    Administer measles-mumps-rubella and varicella vaccines today; defer inactivated vaccines to avoid immune system overload.

Answer

Administer DTaP, Haemophilus influenzae type b, pneumococcal conjugate, and hepatitis A vaccines; defer measles-mumps-rubella and varicella vaccines.
This patient's clinical presentation of prolonged high fever, bilateral nonexudative conjunctivitis, erythema of the oral mucosa, and a polymorphic rash indicates a history of Kawasaki disease. The standard treatment for Kawasaki disease is intravenous immunoglobulin (IVIG) and high-dose aspirin. IVIG contains pooled exogenous IgG antibodies that can bind and neutralize the viruses in live-attenuated vaccines, such as the measles-mumps-rubella (MMR) and varicella vaccines, leading to an inadequate immune response. Because the standard dose of IVIG for Kawasaki disease (2 g/kg) provides high levels of circulating antibodies, live-attenuated vaccines must be deferred for exactly 11 months following treatment. Therefore, at 5 months post-treatment, this patient should not receive the MMR and varicella vaccines. However, inactivated vaccines (DTaP, Haemophilus influenzae type b, pneumococcal conjugate, and hepatitis A) are not affected by circulating exogenous antibodies and should be administered according to the routine catch-up schedule.

Step-by-Step Solution

1
Diagnose the patient's past illness based on the clinical presentation described.
The history of prolonged high fever, bilateral nonexudative conjunctivitis, mucosal changes, and rash indicates Kawasaki disease.
Identifying the disease is necessary to determine the medical treatment he received 5 months ago.
2
Identify the standard treatment administered for Kawasaki disease.
The patient was treated with intravenous immunoglobulin (IVIG) and high-dose aspirin.
Vaccine scheduling is directly impacted by recent administration of blood products like IVIG.
3
Evaluate the effect of recent IVIG on the routine 15-month immunization schedule.
IVIG contains exogenous antibodies that neutralize live-attenuated viral vaccines (MMR and varicella) for up to 11 months. Inactivated vaccines are unaffected.
This determines which vaccines are safe and effective to give today versus which must be delayed.
4
Select the appropriate vaccines to administer and defer.
Administer the overdue inactivated vaccines (DTaP, Hib, PCV, HepA) and defer the live-attenuated vaccines (MMR, varicella) until 11 months post-IVIG.
This strategy maximizes protection against preventable diseases while avoiding ineffective vaccination.

Key Concept

Live-attenuated vaccines must be deferred for up to 11 months following administration of high-dose intravenous immunoglobulin (IVIG) to prevent neutralization by exogenous antibodies, whereas inactivated vaccines can be administered on their normal schedule.
Rate this question

Topics

Preventive Care and Immunizations

More questions from this topic